New hope for kids with Drug-Resistant TB: bedaquiline studied in children
NCT ID NCT02906007
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how safe and tolerable the drug bedaquiline is for children and teens with rifampin-resistant tuberculosis, including those also living with HIV. Fifty-four participants received bedaquiline along with their regular TB treatment for 24 weeks. Researchers measured side effects, heart safety, and how the drug moved through the body to find the right dose for young patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bedaquiline
What this could lead to
If successful, this study could help establish safe and effective dosing of bedaquiline for children with drug-resistant tuberculosis, improving treatment options for this vulnerable group.
What could go wrong
This was a small, early-phase study (54 participants) focused on safety and drug levels, not on cure rates. Side effects like heart rhythm changes and severe adverse events were monitored, and results may not apply to all children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape, 7505, South Africa
-
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, HT-6110, Haiti
-
PHRU Matlosana CRS
Klerksdorp, North West, 2574, South Africa
-
Sizwe CRS
Johannesburg, Gauteng, South Africa